Control of Calcium Entry Signals in B Cells
B 细胞中钙进入信号的控制
基本信息
- 批准号:7993997
- 负责人:
- 金额:$ 37.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-01-01 至 2015-05-31
- 项目状态:已结题
- 来源:
- 关键词:AntibodiesAntibody FormationAntigensApoptosisAutoimmune DiseasesB-LymphocytesBindingBirdsBlood CellsBoratesCalciumCalcium SignalingCell DeathCell LineCell divisionCell membraneCell modelCell physiologyCell surfaceCellsCellular StressChickensChronic Lymphocytic LeukemiaComplexCouplingDevelopmentDifferentiation and GrowthEmployee StrikesEndoplasmic ReticulumFamilyGene DeletionGenerationsGenetic TranscriptionGrowthHeat shock proteinsHumanImmuneImmune System DiseasesImmunityInositolIonsKidneyKineticsKnock-outLifeLymphoproliferative DisordersMaintenanceMediatingMediator of activation proteinMembraneMembrane ProteinsModificationMolecularPhospholipase CPhysiologicalProcessProteinsReceptor ActivationReceptors, Antigen, B-CellRoleSTIM1 geneSignal PathwaySignal TransductionSystemWorkanergyantigen bindingbasecell typecomputerized data processingcrosslinkgenetic regulatory proteinhomologous recombinationhumoral immunity deficiencynoveloperationpreventprotein misfoldingpublic health relevancereceptorreceptor couplingresponsesensorstress protein
项目摘要
DESCRIPTION (provided by applicant): The primary role of B cells, antibody production and antigen elimination, is controlled by the B cell receptor (BCR) complex. BCR crosslinking activates a recently discovered and powerful signaling system mediated by the ER membrane proteins, STIM1 and STIM2. Interacting directly with the PM, STIM proteins expose a reactive domain that avidly binds and traps a specialized family of channel proteins, Orai1, Orai2, and Orai3. The Orai1 channels are exceedingly selective Ca2+ channels that, upon direct binding to STIM sensors, become activated to conduct Ca2+ ions into the junctional cytosolic space. This highly controlled entry of Ca2+ is crucial for two reasons: (i) to replenish Ca2+ within the ER preventing cell stress from protein misfolding, and allowing Ca2+ release signals to be maintained; (ii) to provide longer term and spatially defined Ca2+ signals mediating control over transcription, growth, or apoptosis. The STIM-Orai signaling pathway has particular significance in B cells - the precise coordination of Ca2+ release and entry signals mediates oscillatory Ca2+ signals, the amplitude and duration of which determine how B cells respond to BCR antigen-binding to undergo either proliferation, anergy, or apoptosis. The work combines molecular, biophysical, and cellular approaches to study STIM and Orai proteins using the DT40 B cell line and HEK293 human kidney-derived cells. DT40 B cells retain functional BCR-coupled signaling machinery and we have lines in which each STIM and Orai protein is knocked out. Using these cells our three specific aims are: 1. To examine the distinct functional roles of STIM1 and STIM2 proteins in mediating Ca2+ entry signals. 2. To ascertain how STIM1 and STIM2 proteins interact with and control Orai Ca2+ channels. 3: To examine the STIM-Orai Ca2+ signaling microenvironment in B cells. The studies dissect a novel Ca2+ signaling process fundamentally connected to the BCR-coupled machinery, exerting crucial regulatory control over B cell function. The STIM-Orai signaling pathway and its central role in Ca2+ signal generation in B cells provides a novel and important pharmacological target. The size and duration of Ca2+ signals are primary determinants of B cell fate in response to BCR activ- ation - cell division, maintenance, or, in the case of self-recognition, cell death. Defining the mechanistic operation of this long-acting Ca2+ signaling pathway and examining its pharmacological modification by the borate, 2-APB, provides a target through which B cell function and development can be modified providing the potential to control major immunological diseases including primary B cell deficiencies, lymphoproliferative disorders such as chronic lymphocytic leukemia, and autoimmune diseases.
描述(由申请人提供):B细胞的主要作用是产生抗体和消除抗原,由B细胞受体(BCR)复合体控制。BCR交联激活了最近发现的一个强大的信号系统,该系统由ER膜蛋白STIM1和STIM2介导。STIM蛋白直接与PM相互作用,暴露出一个反应区域,该区域强烈地结合和捕获一个专门的通道蛋白家族Orai1、Orai2和Orai3。Orai1通道是高度选择性的钙通道,一旦直接与STIM感应器结合,就会被激活,将钙离子引导到连接的胞浆空间。这种高度受控的钙离子进入是至关重要的,原因有两个:(I)补充内质网内的钙离子,防止细胞因蛋白质错误折叠而应激,并允许钙释放信号保持;(Ii)提供更长时间和空间上定义的钙信号,介导对转录、生长或凋亡的控制。STIM-Orai信号通路在B细胞中具有特殊的意义--钙释放和进入信号的精确协调介导了振荡的钙信号,其幅度和持续时间决定了B细胞如何响应BCR抗原结合经历增殖、无能或凋亡。这项工作结合了分子、生物物理和细胞方法,使用DT40B细胞系和HEK293人肾来源细胞来研究STIM和ORAI蛋白。DT40B细胞保留有功能的BCR偶联信号机制,我们有每种STIM和ORAI蛋白被敲除的线路。利用这些细胞,我们的三个特定目的是:1.研究STIM1和STIM2蛋白在介导钙内流信号中的不同功能。2.研究STIM1、STIM2蛋白与Orai钙通道的相互作用及调控机制。3.检测B细胞STIM-Orai钙信号微环境。这些研究剖析了一种新的钙信号传递过程,该过程基本上与BCR偶联机制有关,对B细胞功能施加关键的调节控制。STIM-Orai信号通路及其在B细胞钙信号生成中的中心作用提供了一个新的重要的药理靶点。钙信号的大小和持续时间是B细胞在BCR激活时命运的主要决定因素-细胞分裂、维持,或者在自我识别的情况下,细胞死亡。确定这个长效的钙信号通路的机制并研究其被2-APB的药理修饰,提供了一个靶点,通过它可以改变B细胞的功能和发育,从而有可能控制主要的免疫疾病,包括原发的B细胞缺陷,淋巴增殖性疾病,如慢性淋巴细胞白血病和自身免疫性疾病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Donald L Gill其他文献
STIM1 senses both Ca2+ and heat
STIM1 感知钙和热
- DOI:
10.1038/nchembio.587 - 发表时间:
2011-05-17 - 期刊:
- 影响因子:13.700
- 作者:
Salvatore Mancarella;Youjun Wang;Donald L Gill - 通讯作者:
Donald L Gill
Donald L Gill的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Donald L Gill', 18)}}的其他基金
Understanding Store-Operated Calcium Signal Transduction
了解存储操作的钙信号转导
- 批准号:
9926294 - 财政年份:2019
- 资助金额:
$ 37.5万 - 项目类别:
Understanding Store-Operated Calcium Signal Transduction
了解存储操作的钙信号转导
- 批准号:
10601086 - 财政年份:2019
- 资助金额:
$ 37.5万 - 项目类别:
Calcium Signaling Roles of STIM1 and STIM2 in Smooth Muscle
STIM1 和 STIM2 在平滑肌中的钙信号传导作用
- 批准号:
8624181 - 财政年份:2014
- 资助金额:
$ 37.5万 - 项目类别:
Calcium Signaling Roles of STIM1 and STIM2 in Smooth Muscle
STIM1 和 STIM2 在平滑肌中的钙信号传导作用
- 批准号:
8860203 - 财政年份:2014
- 资助金额:
$ 37.5万 - 项目类别:
Calcium Signaling Roles of STIM1 and STIM2 in Smooth Muscle
STIM1 和 STIM2 在平滑肌中的钙信号传导作用
- 批准号:
9018045 - 财政年份:2014
- 资助金额:
$ 37.5万 - 项目类别:
Calcium Signaling Roles of STIM1 and STIM2 in Smooth Muscle
STIM1 和 STIM2 在平滑肌中的钙信号传导作用
- 批准号:
9236203 - 财政年份:2014
- 资助金额:
$ 37.5万 - 项目类别:
相似海外基金
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
- 批准号:
9981001 - 财政年份:2017
- 资助金额:
$ 37.5万 - 项目类别:
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
- 批准号:
9751102 - 财政年份:2017
- 资助金额:
$ 37.5万 - 项目类别:
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
- 批准号:
9397073 - 财政年份:2017
- 资助金额:
$ 37.5万 - 项目类别:
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
- 批准号:
10223410 - 财政年份:2017
- 资助金额:
$ 37.5万 - 项目类别:
PREVENTING NEUTRALIZING ANTIBODY FORMATION IN MS PATIENTS WITH SC IFN-BETA (REBI
使用 SC IFN-β (REBI) 预防 MS 患者中和抗体形成
- 批准号:
7951676 - 财政年份:2008
- 资助金额:
$ 37.5万 - 项目类别:
PREVENTING NEUTRALIZING ANTIBODY FORMATION IN MS PATIENTS WITH SC IFN-β-AL
预防 SC IFN- 多发性硬化症患者中和抗体的形成
- 批准号:
7606036 - 财政年份:2006
- 资助金额:
$ 37.5万 - 项目类别:
IMMUNOLOGIC MECHANISM OF INHIBITOR ANTIBODY FORMATION IN HEMOPHILIA
血友病抑制剂抗体形成的免疫学机制
- 批准号:
7375053 - 财政年份:2005
- 资助金额:
$ 37.5万 - 项目类别:
IMMUNOLOGIC MECHANISM OF INHIBITOR ANTIBODY FORMATION IN HEMOPHILIA
血友病抑制剂抗体形成的免疫学机制
- 批准号:
7201220 - 财政年份:2004
- 资助金额:
$ 37.5万 - 项目类别:
Immunologic Mechanism of Inhibitor Antibody Formation in Hemophilia
血友病抑制剂抗体形成的免疫学机制
- 批准号:
6980810 - 财政年份:2003
- 资助金额:
$ 37.5万 - 项目类别:
INHIBITOR ANTIBODY FORMATION IN HEMOPHILIA AND VON WILLEBRAND'S DISEASE
血友病和冯·维勒布兰德病中的抑制剂抗体形成
- 批准号:
6419444 - 财政年份:2000
- 资助金额:
$ 37.5万 - 项目类别:














{{item.name}}会员




